Explore
Feature Paper in Antibiotics for 2019
0 Ungluers have
Faved this Work
Login to Fave
There has been much speculation about a possible antibiotic Armageddon; this would be the result of having untreatable post-operative infections, and similarly untreatable complications after chemotherapy. The now famous “O’Neill Report” (https://amr-review.org/) suggests that more people could die from resistant bacterial infections by 2050 than from cancer. We are still learning about all the subtle drivers of antibiotic resistance, and realizing that we need a single “whole of health” co-ordinated policy. We ingest what we sometimes feed to animals. There do not seem to be any new classes of antibiotics on our horizon. Perhaps something that has been around “forever” will come to our rescue—bacteriophages! Nevertheless, we have to do things differently, use antibiotics appropriately, for the correct indication, for the correct duration and with the correct dose, and with that, practice good antibiotic stewardship. Whilst by no means comprehensive, this book does cover some of the many topics of antibiotic stewardship. It also addresses some of the older antibiotics, some new combinations, and even some new agents. Last, and by no means least, there are two excellent articles on bacteriophages.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 660 times via unglue.it ebook links.
- 50 - pdf (CC BY) at Unglue.it.
- 596 - pdf (CC BY) at res.mdpi.com.
Keywords
- Acinetobacter baumannii
- actinomycetes
- anti-Candida activity
- antibacterial
- antibacterials
- antibiotic prescribing
- antibiotic resistance
- antibiotic stewardship
- antibiotic utilization
- antibiotics
- antifungal
- antifungals
- antimicrobial resistance
- antimicrobial stewardship
- antimicrobials
- bacteriophages
- behavior change
- Bioactivity
- Biofilms
- biosynthesis
- broad-spectrum agents
- camphorimine
- carbapenem-resistant
- carbapenem-resistant Enterobacteriaceae
- chloramfenicol
- clinical trials
- Cost-effectiveness analysis
- cost-utility analysis
- CRE
- days of therapy
- economic evaluation
- efflux inhibitors
- efflux pumps
- Enterobacteriaceae
- erm(41)
- extended-spectrum beta-lactamases
- florfenicol
- fluoroquinolones
- general practitioners
- guideline
- guidelines
- health equity assessment tool
- health inequalities
- hospital epidemiology
- HPLC–MS/MS
- implementation
- inappropriate prescribing
- infection control
- infection prevention
- Infectious Disease
- medicine
- methicillin-resistant Staphylococcus aureus
- Mutations
- mycobacteria
- n/a
- non-target feed
- novel antimicrobials
- One Health
- out-of-hours care
- phage therapy
- piperine
- piperlongumine
- Policy Analysis
- polyketide synthases
- polyketides
- practitioners cooperative
- primary care
- Pseudomonas aeruginosa
- Public Health
- quality improvement
- quality indicators
- quality of care
- Resistance
- silver complexes
- Singapore
- stakeholder consultation
- Start Smart then Focus
- Swine
- synergy
- thiamfenicol
- urinary tract infections
- Validation
- verapamil
Links
DOI: 10.3390/books978-3-03943-123-6Editions